-
WHO grants emergency usage listing for Covaxin
Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant
-
Covaxin for children likely to be rolled out in phases: Report
According to sero-surveys, India has about 400 million children, of whom nearly 60% or 240 million have already developed antibodies
-
Covaxin gets emergency use approval for kids aged 2-18 years
For final clearance, the recommendations have been sent to the Drugs Controller General of India (DCGI).
-
Indian students can travel to Australia as Covishield get approval down under
Australia had imposed very strict travel restrictions on people travelling in and out of the country
-
Phase 2 and 3 trials of paediatric Covaxin completed
For ramping up production of Covaxin, Bharat Biotech has collaborated with Indian Immunologiclas and Hester Biosciences
-
Bharat Biotech ramps up production of Covaxin with new Gujarat plant
The new facility at Ankleshwar has a manufacturing capacity of more than 1 crore doses per month.
-
Bharat Biotech’s new plant releases first commercial batch of Covaxin
The manufacturer had announced in May that it would produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility.
-
SEC panel approves trial of Covaxin-nasal vaccine mix
Bharat Biotech will be mixing Covaxin, which is administered intramuscularly, with a nasal inoculation based on a different vector.
-
Bharat Biotech terminates MoU with Brazilian partners
The termination comes after the deal with the Brazilian government landed in controversy and attracted a graft probe by authorities
-
Covaxin to get WHO approval at the earliest
According to WHO, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.
